The KCNN4 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human PANC-1 pancreatic cancer cell line. This product offers a stable loss-of-function model for the KCNN4 gene, which encodes the intermediate-conductance calcium-activated potassium channel KCa3.1 (also known as SK4). By disrupting KCNN4 expression, researchers can systematically probe KCa3.1-mediated signaling events and cellular behaviors in a well-characterized pancreatic ductal adenocarcinoma (PDAC) background.
The parental PANC-1 cell line was isolated from a 56-year-old male with pancreatic ductal adenocarcinoma and harbors oncogenic KRAS and TP53 mutations. As a widely used PDAC model, PANC-1 cells display aggressive proliferation and migration. The KCNN4 knockout derivative preserves these genetic features, enabling precise assignment of phenotypic changes to KCNN4 loss.
KCNN4 encodes the KCa3.1 channel, which is activated by calmodulin upon binding to elevated intracellular Ca2+. Upon activation, KCa3.1 mediates K+ efflux, leading to membrane hyperpolarization that enhances Ca2+ influx through Orai1/STIM1 store-operated channels. This sustained Ca2+ rise activates CaMKII and calcineurin; calcineurin dephosphorylates NFAT transcription factors, facilitating their nuclear translocation and transcriptional regulation of target genes such as cyclin D1 and Bcl-2. KCNN4 signaling also intersects with the PI3K/AKT and MAPK/ERK cascades, as demonstrated by modulation of ERK1/2 and AKT phosphorylation. Upstream, KCNN4 is regulated by EGF, TNF-??, IL-1??, and the transcription factors NF-??B and AP-1. Key interacting proteins include calmodulin, Hint1, and caveolin-1. Thus, KCNN4 integrates diverse signals to drive proliferation, survival, and cell motility.
In the KRAS/TP53-mutated PDAC context, KCNN4-mediated calcium signaling contributes to malignant proliferation, migration, and apoptotic resistance. The KCNN4 Knockout PANC-1 Cell Line enables dissection of KCa3.1-dependent mechanisms in cell cycle progression, motility, and intracellular calcium dynamics. This model is particularly valuable for investigating crosstalk between oncogenic KRAS and calcium-regulated pathways, and for evaluating KCa3.1 inhibitors such as TRAM-34 and senicapoc in a disease-relevant setting.
This knockout cell line supports a broad suite of functional assays, including patch-clamp electrophysiology for KCa3.1 current, calcium imaging with Fluo-4, proliferation (MTT, BrdU), migration/invasion (Transwell, wound healing), colony formation, cell cycle analysis, and apoptosis detection by Annexin V. Drug sensitivity profiling with KCa3.1-targeted compounds is directly feasible, as are co-culture experiments modeling the tumor microenvironment. For additional technical details or custom experimental designs, please contact Ascent Research.
